Phaseline

Companies › Heartseed

Heartseed: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Cardiovascular; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HS-005
Allogeneic iPSC-derived cardiomyocyte spheroids transplantation
–Phase 1Heart FailureJan 2028
HS-001 CS
Human allogeneic iPS cell-derived cardiomyocyte spheroids
–Phase 1Heart Failure–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04945018HS-001 CSPhase 1Heart FailureCardiovascularJul 2025
NCT07347197HS-005Phase 1Heart FailureCardiovascularJan 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.